InsiderTrades.com logo
Rare "crisis signal" triggers for third time in U.S. market
From Stansberry Research   |   Ad
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
Click here for all the details. 
Eric A. Adams net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Eric Adams Biography and Net Worth

CEO of InMed Pharmaceuticals

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in

capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well-respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies.

He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.

What is Eric A. Adams' net worth?

The estimated net worth of Eric A. Adams is at least $9,666.80 as of February 20th, 2024. Mr. Adams owns 2,197 shares of InMed Pharmaceuticals stock worth more than $9,667 as of December 22nd. This net worth evaluation does not reflect any other investments that Mr. Adams may own. Additionally, Mr. Adams receives a salary of $347,820.00 as CEO at InMed Pharmaceuticals. Learn More about Eric A. Adams' net worth.

How old is Eric A. Adams?

Mr. Adams is currently 61 years old. There are 5 older executives and no younger executives at InMed Pharmaceuticals. Learn More on Eric A. Adams' age.

What is Eric A. Adams' salary?

As the CEO of InMed Pharmaceuticals Inc., Mr. Adams earns $347,820.00 per year. Learn More on Eric A. Adams' salary.

How do I contact Eric A. Adams?

The corporate mailing address for Mr. Adams and other InMed Pharmaceuticals executives is , , . InMed Pharmaceuticals can also be reached via phone at 604-669-7207 and via email at [email protected]. Learn More on Eric A. Adams' contact information.

Has Eric A. Adams been buying or selling shares of InMed Pharmaceuticals?

Eric A. Adams has not been actively trading shares of InMed Pharmaceuticals during the last ninety days. Most recently, on Tuesday, February 20th, Eric A. Adams bought 2,080 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $7.20 per share, with a total value of $14,976.00. Following the completion of the transaction, the chief executive officer now directly owns 2,197 shares of the company's stock, valued at $15,818.40. Learn More on Eric A. Adams' trading history.

Who are InMed Pharmaceuticals' active insiders?

InMed Pharmaceuticals' insider roster includes Eric Adams (CEO), Bruce Colwill (CFO), and Shane Johnson (SVP). Learn More on InMed Pharmaceuticals' active insiders.

Are insiders buying or selling shares of InMed Pharmaceuticals?

During the last twelve months, InMed Pharmaceuticals insiders bought shares 2 times. They purchased a total of 3,955 shares worth more than $29,601.00. The most recent insider tranaction occured on February, 21st when Director Andrew Hull bought 1,875 shares worth more than $14,625.00. Insiders at InMed Pharmaceuticals own 1.9% of the company. Learn More about insider trades at InMed Pharmaceuticals.

Information on this page was last updated on 2/21/2024.

Eric A. Adams Insider Trading History at InMed Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2024Buy2,080$7.20$14,976.002,197View SEC Filing Icon  
4/13/2022Buy428$17.00$7,276.002,242View SEC Filing Icon  
9/28/2021Buy570$35.00$19,950.00View SEC Filing Icon  
See Full Table

Eric A. Adams Buying and Selling Activity at InMed Pharmaceuticals

This chart shows Eric A Adams's buying and selling at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Company Overview

InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $4.40
Low: $4.14
High: $4.51

50 Day Range

MA: $4.94
Low: $4.05
High: $7.10

2 Week Range

Now: $4.40
Low: $2.41
High: $15.70

Volume

40,444 shs

Average Volume

113,510 shs

Market Capitalization

$3.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3
Rare "crisis signal" triggers for third time in U.S. market
From Stansberry Research   |   Ad
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
Click here for all the details.